business

Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term

Possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin. We continue to believe this opportunity is more suitable for investors with high risk appetite and those who are ready to hold it long enough for the product pipeline to unfold

first published: May 14, 2021 06:07 pm

LATEST VIDEOS

Watch More →

A collection of the most-viewed Moneycontrol videos.

Ideas for Profit

Watch More →

Is it a good time to enter Bajaj Finance post Q3 business update? | Opening Bell

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347